Rapid Platform (R6.7)
Ischemaview, Inc. · Decision date Sep 21, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 21, 2026 for K261368, the Rapid Platform (R6.7) submitted by Ischemaview, Inc. of Golden, Colorado. The submission is a traditional 510(k) under 21 CFR 892.2050, classified as Automated Radiological Image Processing Software in the Radiology panel, with primary product code QIH and subsequent codes LLZ, POK, PZO, QAS and QFM. The public database lists a receipt date of April 27, 2026, while the FDA letter cites a device-dated date of August 18, 2026 and a received date of August 19, 2026; the discrepancy is unexplained in the available text.
The clearance covers a software platform that performs viewing, processing and analysis of DICOM-compliant CT and MRI data, coordinating modules such as CTP/MRP, CTA, ASPECTS, ICH, LVO and NCCT Stroke. The summary names iSchemaView Rapid (K233512) as primary predicate and lists earlier clearances including K121447 and K213165. SESE means clearance to market, not PMA approval. The available documents do not state performance testing results, so the evidentiary basis for the equivalence determination remains unknown.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 21, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261368
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Ischemaview, Inc.
- Product code
- QIH
- Decision code
- SESE
- Decision date
- Sep 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated Radiological Image Processing Software.
- Applicant
- Ischemaview, Inc.
- Product code
- QIH
- FDA device class
- 2
FDA decision timeline
K261368 received
Application receipt date recorded by FDA.
K261368 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Clever OneK260372 | Ewoosoft Co., Ltd. | 510(k) clearance | Nov 4, 2026 | FDA |
PeekMed webK262667 | Peek Health, S.A. | 510(k) clearance | Nov 4, 2026 | FDA |
CINA-Aneurysm+K262147 | AVICENNA.AI | 510(k) clearance | Oct 19, 2026 | FDA |
Ligence HeartK261733 | UAB Ligence | 510(k) clearance | Oct 7, 2026 | FDA |
NeuroDRK262134 | Deep Reasoning Ai, Inc. | 510(k) clearance | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ischemaview, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Golden, CO
Sources and methodology
- Original FDA record: K261368
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


